Thera-SAbDab

TILDRAKIZUMAB

> Structural Summary

Therapeutic	Tildrakizumab
Target	IL23A
Heavy Chain	QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2012
INN Year Recommended	2013
Companies Involved	Almirall S.A., Merck & Co, Schering-Plough, Sun Pharmaceutical Industries
Conditions Approved	Plaque psoriasis
Conditions Active	Ankylosing spondylitis, Intervertebral disc degeneration, Non-radiographic axial spondyloarthritis, Psoriatic arthritis
Conditions Discontinued	Autoimmune disorders
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]